Anti-PCSK9 Rabbit Polyclonal Antibody
- Host
- Rabbit, Polyclonal
- Reactivity
- Human, Mouse, Rat
- UniProt
- Q8NBP7
- Size
- 100 µL
- Cat. #
- RP-PCSK9
In stock
- SKU
- RP-PCSK9
Rabbit polyclonal antibody against PCSK9 (Proprotein Convertase Subtilisin/Kexin type 9). PCSK9 is a secreted subtilisin-family serine protease widely known as the master regulator of LDL receptor (LDLR) turnover. Circulating PCSK9 binds the LDLR extracellularly and directs the LDLR-PCSK9 complex to lysosomal degradation, elevating serum LDL cholesterol.
Gain-of-function mutations in PCSK9 cause autosomal dominant familial hypercholesterolemia, while loss-of-function variants (particularly R46L, Y142X, C679X) protect against cardiovascular disease. This inverse genetics has driven development of therapeutic monoclonal antibodies (evolocumab, alirocumab, tafolecimab) and siRNA (inclisiran) that lower LDL cholesterol by 50–70%. Beyond LDLR regulation, PCSK9 modulates VLDL, apolipoprotein B secretion, hepatocyte inflammation, and possibly innate immunity via CD36 and other cell-surface receptors.
The RP4 clone targets the C-terminal Cys/His-rich domain (CHRD), which mediates PCSK9 self-oligomerization and enhances LDLR binding avidity. This domain is preserved across mammals with >90% sequence identity.
Applications: Western blot validated (RP4). Recommended positive controls: HepG2 hepatocellular lysate (endogenous), transfected HEK293 with human PCSK9, or human serum (dilute 1:20). The pro-form (~74 kDa) is autocleaved to the mature form (~62 kDa) in the ER; both are detectable with this antibody.
Immunogen: Synthetic peptide corresponding to the C-terminal CHRD of human PCSK9 (UniProt Q8NBP7).
Reactivity: Human confirmed; mouse and rat cross-reactivity predicted.
Additional Specifications
| Size | 100 µg |
|---|---|
| Target Protein | PCSK9 |
| UniProt ID | Q8NBP7 |
| Gene Symbol | PCSK9 |
| Host Species | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Immunogen | Synthetic peptide corresponding to the C-terminal cysteine/histidine-rich domain (CHRD) of human PCSK9 (UniProt Q8NBP7). |
| Conjugation | Unconjugated |
| Formulation | PBS, 0.02% sodium azide, 50% glycerol |
| Storage Conditions | -20°C long-term; 4°C short-term (≤1 month); avoid repeated freeze-thaw |
| Reactivity Species | Human |
| Validated Applications | Western Blot (WB) |
| Recommended Dilution | WB 1:1000 |
| Volume / Size | 100 µL |
| Proteinase Class | Serine Proteinase |
| Purity (%) | >95% (affinity purified) |
| Publication Citations | 0 |
| Alternate Names | Proprotein convertase subtilisin/kexin type 9 · Neural apoptosis-regulated convertase 1 · NARC-1 |
| References (HTML) |
|
| Potential Cross-Reactivity | Mouse, Rat |
Validation imagery coming soon
Western blot validation figures for PCSK9 will be published here as they are produced in-house.
If you would like to see existing validation data for this antibody before publication, request a sample copy.
Also known as:
- Proprotein convertase subtilisin/kexin type 9
- Neural apoptosis-regulated convertase 1
- NARC-1
- UniProt Consortium. (2023) UniProt: the Universal Protein Knowledgebase in 2023. Nucleic Acids Res. 51(D1):D523–D531.
- Rawlings ND, Barrett AJ, Thomas PD, Huang X, Bateman A, Finn RD. (2018) The MEROPS database of proteolytic enzymes, their substrates and inhibitors in 2017. Nucleic Acids Res. 46(D1):D624–D632.
Help us track citations using this antibody — email us your DOI when your paper is accepted.